Association Between Glycated Hemoglobin (HbA1c) and the Lipid Profile in Patients with Type 2 Diabetes Mellitus at a Tertiary Care Hospital: A Retrospective Study
Authors/Creators
- 1. Assistant Professor, Department of Biochemistry, Govt. Medical College, Kota, Rajasthan
- 2. Senior Professor and Head, Department of Biochemistry, Govt. Medical College, Kota, Rajasthan
- 3. Assistant Professor, Department of Biochemistry, SPMC, Medical College, Bikaner, Rajasthan
Description
Background: HbA1C is not only a glycemic index but can also be used as a marker of dyslipidemia and thus can be used as a preventive measure for the development of CVD in patients with T2DM. Methods: This retrospective cross-sectional study was conducted during the year 2012-13. Venous blood samples were collected from 300 type 2 diabetic patients. The sera were analyzed for HbA1c, fasting blood glucose (FBG) and lipid profile panel test. Dyslipidemia was defined as per the National Cholesterol Education Programme (NCEP) Adult Treatment Panel (ATP) III guidelines. Diabetes was defined as per American diabetes association criteria. The statistical analysis was done on Microsoft excel and Epi info-6 software. Result: In our present study 95(81.89%) females out of 116 and 151 (82.06 %) males out of 184 were dyslipidemic. HbA1c demonstrated positive and significant correlations with total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipopro-tein cholesterol (HDL-C) and LDL-C. Patients with HbA1c value > 7.0% had significantly higher value of TC, Triacylglycerol (TAG), LDL-C, HDL-C as compared to the patients with HbA1c ≤ 7.0%. HbA1c can be used as a biomarker for predicting dyslipidemia in type 2 diabetic patients in addition to glycemic control.
Abstract (English)
Background: HbA1C is not only a glycemic index but can also be used as a marker of dyslipidemia and thus can be used as a preventive measure for the development of CVD in patients with T2DM. Methods: This retrospective cross-sectional study was conducted during the year 2012-13. Venous blood samples were collected from 300 type 2 diabetic patients. The sera were analyzed for HbA1c, fasting blood glucose (FBG) and lipid profile panel test. Dyslipidemia was defined as per the National Cholesterol Education Programme (NCEP) Adult Treatment Panel (ATP) III guidelines. Diabetes was defined as per American diabetes association criteria. The statistical analysis was done on Microsoft excel and Epi info-6 software. Result: In our present study 95(81.89%) females out of 116 and 151 (82.06 %) males out of 184 were dyslipidemic. HbA1c demonstrated positive and significant correlations with total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipopro-tein cholesterol (HDL-C) and LDL-C. Patients with HbA1c value > 7.0% had significantly higher value of TC, Triacylglycerol (TAG), LDL-C, HDL-C as compared to the patients with HbA1c ≤ 7.0%. HbA1c can be used as a biomarker for predicting dyslipidemia in type 2 diabetic patients in addition to glycemic control.
Files
IJPCR,Vol14,Issue6,Article44.pdf
Files
(189.9 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:fc67a9a3a6c122c76f196eb30a990dc0
|
189.9 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-06-05
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/14/IJPCR,Vol14,Issue6,Article44.pdf
- Development Status
- Active
References
- 1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004:27 (5):1047-53 2. Robbins and Cortan Pathologic Basis of Disease (7th ed.) Philadelphia, Pa.: Saunders.pp.1194-1195. 3. Diabtes.http://.who.int/mediacentre/fac tsheets/fs312/en/ index.html (Updated on November 2009). 4. Glycosylaed Haemoglobin, HbA1C.hptt:// clinlabnavigator.com/testinterpretations/haemoglobin-a1c.html? letter=h (Updated on 18 June 2010). 5. Lily. Diabetic dyslipidemia. Chapter 97. In: Medicine update. 2000; 10:547. 6. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234. 7. Windler E. What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome? Atheroscler Suppl 2005; 6:11-14. 8. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosy-lated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 14: 421-431. 9. Khaw KT, Wareham N, Bingham S, Luben R, Welch A and Day N. Association of hemoglobin A1c with car-diovascular disease and mortality in adults: the Euro-pean Prospective Investigation into Cancer in Norfolk. Ann Intern Med 2004; 141: 413-420. 10. Hill JB, Kessler G. An automated determination of glucose utilizing a glucose oxidase-peroxidase system. J Lab Clin Med 1961; 57: 970-980. 11. Deeg R, Ziegenhorn J. Kinetic enzymatic method for automated determination of total cholesterol in serum. Clin Chem 1983; 29: 1798-802. 12. Bucolo G, David H. Quantitative determination of se-rum triglycerides by the use of enzymes. Clin Chem 1973; 19: 476-482. Assmann G, Schriewer H, Schmitz G, H�gele EO. Quantification of high-densitylipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem 1983; 29: 2026-2030. 13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502. 14. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [spe-cial communication]. JAMA 2001; 285:2486- 2497. 15. American Diabetes Association. Diagnosis and classifi-cation of Diabetes Mellitus. Diabetes Care 2010; 33: s6 2-s69. 16. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005; 28: 514-520. 17. Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabe-tes Care 2005; 28: 2472-2479. 18. Sibley SD, Thomas W, de Boer I, Brunzell JD, Steffes MW. Gender and elevated albumin excretion in the Diabetes Control and Complications trial/ Epidemiol-ogy of Diabetes Interventions and Complications (DCCT/EDIC) cohort: role of central obesity. Am J Kidney Dis 2006; 47: 223-232.19. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996; 37: 693-707. 20. Tavangar K, Murata Y, Pedersen ME, Goers JF, Hoff-man AR, Kraemer FB. Regulation of lipoprotein lipase in the diabetic rat. J Clin Invest 1992; 90: 1672-1678. 21. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453–458. 22. Andersen G, Christiansen J, Mortensen H, et al. Plasma lipid and lipoprotein in type 1 diabetic children and adolescent in relation to metabolic regulation, obesity and genetic hyperlipoprotenimia. Acta Paediatr Scand 1983; 72: 361–365. 23. Erciyas F, Taneli F, Arslan B, et al. Glycemic control, oxidative stress, and lipid profile in children with type 1 diabetes mellitus. Arch Med Res 2004; 35: 134–140. 24. Ohta T, Nishiyama S, Nakamura T, et al. Predominance of large low density lipoprotein particles and lower fractional esterification rate of cholesterol in high density lipoprotein in children with insulin-dependent diabetes mellitus. Eur J Pediatr 1998; 157: 276–281. 25. Firdous S, Khan M. Comparison of patterns of lipid profile in type-2 diabetics and non-diabetics. Ann King Edward Med Coll 2007; 13: 84–87. 26. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship be-tween plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Com-plications trial. Diabetes Care 2002; 25: 275-278. 27. Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med 2007; 7: 24-29. 28. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2006; 29: 877-882. 29. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPICNorfolk). Br Med J 2001; 322: 15-18.